Sunphenon in Progressive Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG)
treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more
effective than an oral placebo treatment regarding following parameters: increase in brain
atrophy, number of new T2-lesions in the cerebral magnetic resonance tomography, reduction of
the NAA/Cr-ratio in MR-spectroscopy, progression of disability such as cognitive disorders in
patients with MS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Charite University, Berlin, Germany Friedemann Paul